Section Arrow
Quote
REGN.NASDAQ
- Regeneron Pharmaceuticals
Quotes are at least 15-min delayed:2026/07/16 02:51 EDT
Regular Hours
Last
 664.45
+8.33 (+1.27%)
Day High 
669.1 
Prev. Close
656.12 
1-M High
677.92 
Volume 
555.42K 
Bid
649.66
Ask
672
Day Low
648.66 
Open
656.11 
1-M Low
594.9 
Market Cap 
68.79B 
Currency 美元 
P/E 16.02 
%Yield 0.55 
10-SMA 654.31 
20-SMA 636.48 
50-SMA 647.68 
52-W High 821.11 
52-W Low 541 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
40.96/47.74
Enterprise Value
71.49B
Balance Sheet
Book Value Per Share
299.73
Cash Flow
Cash Flow Yield
0.07
Income Statement
Total Revenue
14.34B
Operating Revenue Per Share
124.93
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
VIVSVivoSim Lab Inc0.8529+0.0181+2.17%0.47PE
LIMNLiminatus Pharma Inc0.1145+0.011+10.63%-- 
IOVAIovance Biotherapeutics4.74+0.81+20.61%-- 
KAPAKairos Pharma Ltd.0.318-0.022-6.47%-- 
PHIOPhio Pharmaceuticals Corp0.8901-0.1399-13.58%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approvedfor wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.